Retinoblastoma tumorigenesis

Genetic and epigenetic changes walk hand in hand

Petra Temming, Timothy Corson, Dietmar R. Lohmann

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Evaluation of: Zhang J, Benavente CA, McEvoy J et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481(7381), 329-334 (2012). The rate-limiting step in retinoblastoma tumorigenesis is inactivation of both RB1 alleles, but it has remained unclear how this tumor acquires the additional changes that constitute a malignant phenotype. Zhang et al. characterized the genetic and epigenetic alterations in four retinoblastomas using whole-genome analysis techniques. In these samples, the retinoblastoma genome was found to be remarkably stable genetically, although recurrent mutations in BCOR were identified in 13% of patients. However, an approach that integrated the results of ChIP, methylation and expression analysis identified multiple, more frequent alterations of the epigenetic landscape. One of the leading genes on the list the authors obtained was SYK, a kinase epigenetically upregulated. Knockdown of this gene and exposure to small molecules inhibiting the kinase function stopped tumor growth in vitro and in vivo, thus offering a new therapeutic target for the treatment of retinoblastoma.

Original languageEnglish
Pages (from-to)525-528
Number of pages4
JournalFuture Oncology
Volume8
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Retinoblastoma
Epigenomics
Carcinogenesis
Phosphotransferases
Genome
Gene Knockdown Techniques
Methylation
Neoplasms
Therapeutics
Alleles
Phenotype
Mutation
Growth
Genes

Keywords

  • BCOR
  • DNA methylation
  • epigenetic regulation
  • gene expression
  • histone modification
  • RB1
  • retinoblastoma
  • SYK
  • tumorigenesis
  • whole-genome sequencing

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Retinoblastoma tumorigenesis : Genetic and epigenetic changes walk hand in hand. / Temming, Petra; Corson, Timothy; Lohmann, Dietmar R.

In: Future Oncology, Vol. 8, No. 5, 05.2012, p. 525-528.

Research output: Contribution to journalArticle

Temming, Petra ; Corson, Timothy ; Lohmann, Dietmar R. / Retinoblastoma tumorigenesis : Genetic and epigenetic changes walk hand in hand. In: Future Oncology. 2012 ; Vol. 8, No. 5. pp. 525-528.
@article{a7fc623bba7c4f88a0ee0af1b8950b57,
title = "Retinoblastoma tumorigenesis: Genetic and epigenetic changes walk hand in hand",
abstract = "Evaluation of: Zhang J, Benavente CA, McEvoy J et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481(7381), 329-334 (2012). The rate-limiting step in retinoblastoma tumorigenesis is inactivation of both RB1 alleles, but it has remained unclear how this tumor acquires the additional changes that constitute a malignant phenotype. Zhang et al. characterized the genetic and epigenetic alterations in four retinoblastomas using whole-genome analysis techniques. In these samples, the retinoblastoma genome was found to be remarkably stable genetically, although recurrent mutations in BCOR were identified in 13{\%} of patients. However, an approach that integrated the results of ChIP, methylation and expression analysis identified multiple, more frequent alterations of the epigenetic landscape. One of the leading genes on the list the authors obtained was SYK, a kinase epigenetically upregulated. Knockdown of this gene and exposure to small molecules inhibiting the kinase function stopped tumor growth in vitro and in vivo, thus offering a new therapeutic target for the treatment of retinoblastoma.",
keywords = "BCOR, DNA methylation, epigenetic regulation, gene expression, histone modification, RB1, retinoblastoma, SYK, tumorigenesis, whole-genome sequencing",
author = "Petra Temming and Timothy Corson and Lohmann, {Dietmar R.}",
year = "2012",
month = "5",
doi = "10.2217/fon.12.41",
language = "English",
volume = "8",
pages = "525--528",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Retinoblastoma tumorigenesis

T2 - Genetic and epigenetic changes walk hand in hand

AU - Temming, Petra

AU - Corson, Timothy

AU - Lohmann, Dietmar R.

PY - 2012/5

Y1 - 2012/5

N2 - Evaluation of: Zhang J, Benavente CA, McEvoy J et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481(7381), 329-334 (2012). The rate-limiting step in retinoblastoma tumorigenesis is inactivation of both RB1 alleles, but it has remained unclear how this tumor acquires the additional changes that constitute a malignant phenotype. Zhang et al. characterized the genetic and epigenetic alterations in four retinoblastomas using whole-genome analysis techniques. In these samples, the retinoblastoma genome was found to be remarkably stable genetically, although recurrent mutations in BCOR were identified in 13% of patients. However, an approach that integrated the results of ChIP, methylation and expression analysis identified multiple, more frequent alterations of the epigenetic landscape. One of the leading genes on the list the authors obtained was SYK, a kinase epigenetically upregulated. Knockdown of this gene and exposure to small molecules inhibiting the kinase function stopped tumor growth in vitro and in vivo, thus offering a new therapeutic target for the treatment of retinoblastoma.

AB - Evaluation of: Zhang J, Benavente CA, McEvoy J et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481(7381), 329-334 (2012). The rate-limiting step in retinoblastoma tumorigenesis is inactivation of both RB1 alleles, but it has remained unclear how this tumor acquires the additional changes that constitute a malignant phenotype. Zhang et al. characterized the genetic and epigenetic alterations in four retinoblastomas using whole-genome analysis techniques. In these samples, the retinoblastoma genome was found to be remarkably stable genetically, although recurrent mutations in BCOR were identified in 13% of patients. However, an approach that integrated the results of ChIP, methylation and expression analysis identified multiple, more frequent alterations of the epigenetic landscape. One of the leading genes on the list the authors obtained was SYK, a kinase epigenetically upregulated. Knockdown of this gene and exposure to small molecules inhibiting the kinase function stopped tumor growth in vitro and in vivo, thus offering a new therapeutic target for the treatment of retinoblastoma.

KW - BCOR

KW - DNA methylation

KW - epigenetic regulation

KW - gene expression

KW - histone modification

KW - RB1

KW - retinoblastoma

KW - SYK

KW - tumorigenesis

KW - whole-genome sequencing

UR - http://www.scopus.com/inward/record.url?scp=84861724937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861724937&partnerID=8YFLogxK

U2 - 10.2217/fon.12.41

DO - 10.2217/fon.12.41

M3 - Article

VL - 8

SP - 525

EP - 528

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 5

ER -